LTF and retinoblastoma: Narayana et al. (2021) produced lactoferrin protein nanoparticles (LFNPs)—targeting the prominent lactoferrin (LF) receptors in tumor cells due to increased iron demand—to treat retinoblastoma and mitigate chemoresistance to carboplatin (CRB) and etoposide (ETP).